FDA greenlights Adaptimmune cell therapy

Adaptimmune Therapeutics has announced that the FDA has granted accelerated approval for Tecelra (afamitresgene autoleucel), a treatment specifically designed for adults with advanced MAGE-A4+ synovial sarcoma who possess certain HLA types and have previously received chemotherapy. This breakthrough marks the first FDA approval of an engineered cell therapy for solid tumors, highlighting a significant advancement in the treatment of synovial sarcoma, which hasn't seen a new therapy in over ten years.

Tecelra is a genetically modified autologous T-cell immunotherapy. Its approval was based on the results of the spearhead-1 trial, which involved 44 patients and showed a promising overall response rate (ORR) and duration of response. The therapy achieved an ORR of 43% and a complete response rate of 4.5%. Notably, 39% of those who responded to the therapy maintained their response for 12 months or more. However, the approval is conditional on further verification and detailed description of the clinical benefits in a follow-up confirmatory trial.

The mechanism of Tecelra involves modifying the patient's own T-cells to enable them to target and attack cancer cells. The process starts by extracting T-cells from the patient, which are then genetically engineered to identify the MAGE-A4 antigen present on the cancer cells. These modified T-cells are subsequently reintroduced into the patient's body to combat the tumor more effectively.

To facilitate the implementation of Tecelra, Adaptimmune is launching a support initiative known as AdaptimmuneAssist. This program is designed to aid in the treatment process and ensure patient access to the new therapy. Moreover, Adaptimmune intends to establish six to ten authorized treatment centers this year, with plans to expand to approximately 30 centers within the next two years.

This development represents a significant milestone in cancer treatment, particularly for those suffering from synovial sarcoma, providing new hope and options for patients who have had limited alternatives in the past.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!